It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Type 2 diabetes mellitus (T2D) is often accompanied by chronic diseases, including mental health problems. We aimed at studying mental health comorbidity prevalence in T2D patients and its association with T2D outcomes through a retrospective, observational study of individuals of the EpiChron Cohort (Aragón, Spain) with prevalent T2D in 2011 (n = 63,365). Participants were categorized as having or not mental health comorbidity (i.e., depression, anxiety, schizophrenia, and/or substance use disorder). We performed logistic regression models, controlled for age, sex and comorbidities, to analyse the likelihood of 4-year mortality, 1-year all-cause hospitalization, T2D-hospitalization, and emergency room visit. Mental health comorbidity was observed in 19% of patients. Depression was the most frequent condition, especially in women (20.7% vs. 7.57%). Mortality risk was higher in patients with mental health comorbidity (odds ratio 1.24; 95% confidence interval 1.16–1.31), especially in those with substance use disorder (2.18; 1.84–2.57) and schizophrenia (1.82; 1.50–2.21). Mental health comorbidity also increased the likelihood of all-cause hospitalization (1.16; 1.10–1.23), T2D-hospitalization (1.51; 1.18–1.93) and emergency room visit (1.26; 1.21–1.32). These results suggest that T2D healthcare management should include specific strategies for the early detection and treatment of mental health problems to reduce its impact on health outcomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 IIS Aragón, Teaching Unit of Preventive Medicine and Public Health, EpiChron Research Group, Zaragoza, Spain (GRID:grid.488737.7) (ISNI:0000000463436020)
2 Aragon Health Sciences Institute (IACS), IIS Aragón, Health Services Research On Chronic Patients Network (REDISSEC), Miguel Servet University Hospital, EpiChron Research Group, Zaragoza, Spain (GRID:grid.411106.3) (ISNI:0000 0000 9854 2756)
3 IIS Aragón, REDISSEC, University of Zaragoza, Servicio Aragonés de Salud (SALUD), Primary Care Health Centre San Pablo, EpiChron Research Group, Zaragoza, Spain (GRID:grid.11205.37) (ISNI:0000 0001 2152 8769)
4 IIS Aragón, EpiChron Research Group, Zaragoza, Spain (GRID:grid.488737.7) (ISNI:0000000463436020)
5 IBIMA, University of Malaga, CIBERDEM, Regional University Hospital of Málaga, Endocrinology and Nutrition Department, Málaga, Spain (GRID:grid.10215.37) (ISNI:0000 0001 2298 7828)
6 Institute of Health Carlos III, REDISSEC, National Centre of Epidemiology, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)